Literature DB >> 1136331

An immune hemagglutination procedure with very high sensitivity applied to the detection of hepatitis B antibody and antigen and immune complex.

J H Pert, R L Verch.   

Abstract

An immune agglutination procedure is described in which red cells are coated with antigen and agglutination is observed after a short incubation with antibody in reagent serum. Conversely, the cells may be coated with antibody and used to test for the presence of antigen. Treatment of the reagent serum with cobra venom factor results in inhibition, and there is a marked lo-s of sensitivity with cells pretreated with formalin or chromic chloride, suggesting that C3 and some type of reactive sites on the cells are required. The distinctive features of the new procedure are that incubation time is very short, sensitivity is several orders of magnitude higher than with other related tests, and, within some limitations, bovine (steer) red cells with bovine serum can be used as an alternative to human red cells with human serum. It is necessary to remove an inhibitor from the reagent serum, human or steer. While the mechanism of the procedure needs further elucidation, the findings reported here suggest that it ought to be sufficiently sensitive to detect hepatitus B antigen if present in virtually any blood sample. With appropriate modifications it should be useful for blood donor screening, diagnosis, and for studying many other antigen-antibody systems.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1136331     DOI: 10.1111/j.1423-0410.1975.tb00491.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  2 in total

1.  Development and use of a micro haemagglutination inhibition (HAI) technique, based on Hepatest, for the detection and quantitation of hepatitis B surface antibody (Anti-HBs) in blood donors.

Authors:  I C Wiseman
Journal:  J Clin Pathol       Date:  1977-01       Impact factor: 3.411

2.  Preparation and use of erythrocyte-globulin conjugates to Lassa virus in reversed passive hemagglutination and inhibition.

Authors:  R A Goldwasser; L H Elliott; K M Johnson
Journal:  J Clin Microbiol       Date:  1980-06       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.